Wedbush Has Bearish Forecast for VRDN FY2027 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Wedbush reduced their FY2027 earnings per share estimates for Viridian Therapeutics in a note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $3.77 for the year, down from their prior estimate of $3.81. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics’ FY2027 earnings at $3.77 EPS, FY2028 earnings at $9.42 EPS and FY2028 earnings at $9.42 EPS.

A number of other equities research analysts have also issued reports on VRDN. Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. TD Cowen began coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating on the stock. Royal Bank of Canada upped their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Stock Up 1.6 %

Shares of Viridian Therapeutics stock opened at $15.53 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20. The company’s 50 day moving average price is $18.20 and its 200-day moving average price is $19.63. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.60 and a beta of 1.32.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Institutional Trading of Viridian Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Viridian Therapeutics by 29.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,782 shares of the company’s stock worth $2,220,000 after purchasing an additional 26,286 shares during the period. Tang Capital Management LLC boosted its position in shares of Viridian Therapeutics by 11.1% in the 4th quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company’s stock worth $47,789,000 after purchasing an additional 250,000 shares in the last quarter. Rafferty Asset Management LLC grew its stake in shares of Viridian Therapeutics by 90.8% in the 4th quarter. Rafferty Asset Management LLC now owns 172,960 shares of the company’s stock worth $3,316,000 after buying an additional 82,309 shares during the last quarter. ProShare Advisors LLC increased its position in Viridian Therapeutics by 74.1% during the 4th quarter. ProShare Advisors LLC now owns 20,584 shares of the company’s stock valued at $395,000 after buying an additional 8,761 shares in the last quarter. Finally, Parkman Healthcare Partners LLC raised its stake in Viridian Therapeutics by 155.9% during the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company’s stock valued at $20,850,000 after buying an additional 662,634 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.